DK1124804T3 - Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase - Google Patents

Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase

Info

Publication number
DK1124804T3
DK1124804T3 DK99953259T DK99953259T DK1124804T3 DK 1124804 T3 DK1124804 T3 DK 1124804T3 DK 99953259 T DK99953259 T DK 99953259T DK 99953259 T DK99953259 T DK 99953259T DK 1124804 T3 DK1124804 T3 DK 1124804T3
Authority
DK
Denmark
Prior art keywords
cox
inhibitors
cyclooxygenase
biosynthesis
synthase
Prior art date
Application number
DK99953259T
Other languages
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyj Kolasa
Michael E Kort
Meena V Patel
Jeffrey J Rohde
Michael J Coghlan
Andrew O Stewart
Huaqing Liu
Catherine M Mccarty
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Application granted granted Critical
Publication of DK1124804T3 publication Critical patent/DK1124804T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99953259T 1998-10-27 1999-10-27 Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase DK1124804T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
DK1124804T3 true DK1124804T3 (da) 2005-12-12

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99953259T DK1124804T3 (da) 1998-10-27 1999-10-27 Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase

Country Status (19)

Country Link
EP (1) EP1124804B1 (da)
JP (1) JP2003512292A (da)
KR (1) KR100666838B1 (da)
CN (1) CN1279026C (da)
AT (1) ATE302759T1 (da)
BG (1) BG65261B1 (da)
BR (1) BR9914858A (da)
CA (1) CA2347982A1 (da)
CZ (1) CZ300570B6 (da)
DE (1) DE69926903T2 (da)
DK (1) DK1124804T3 (da)
ES (1) ES2249919T3 (da)
HK (1) HK1041876B (da)
HU (1) HUP0105248A3 (da)
NO (1) NO318623B1 (da)
PL (1) PL198503B1 (da)
SK (1) SK286806B6 (da)
TR (1) TR200101765T2 (da)
WO (1) WO2000024719A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738595B2 (en) 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−3−オン誘導体及びこれを含有する医薬
WO2001041760A2 (en) 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
TWI290130B (en) 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
CN100486576C (zh) 2002-02-14 2009-05-13 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−2−δリガンド
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
RU2005132167A (ru) 2003-03-18 2006-05-10 Кова Ко., Лтд. (Jp) Водорастворимые производные фенилпиридазина и лекарственные средства, содержащие их
JP4354984B2 (ja) 2003-05-07 2009-10-28 オステオロジックス エイ/エス 水溶性ストロンチウム塩を用いる軟骨/骨症状の治療
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
JP5308350B2 (ja) 2006-12-22 2013-10-09 レコルダーティ アイルランド リミテッド α2δリガンドおよびNSAIDを用いた下部尿路機能障害の併用療法
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008839A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007020689A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
CN101809021B (zh) 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd 4位置換ピリダジノン化合物及びp2x7受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EP3509604B1 (en) 2016-09-07 2026-02-18 Trustees of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
WO1982000402A1 (en) * 1980-08-07 1982-02-18 Shamrock Corp Diamond Herbicidal and plant growth regulant diphenylpyridazinones
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
DE69825154T2 (de) * 1997-03-14 2005-07-21 Merck Frosst Canada & Co, Kirkland Pyridazinone als inhibitoren von cyclooxygenase-2
PT1005460E (pt) * 1997-08-22 2006-07-31 Abbott Lab Biossintese de inibidores de prostaglandina-endoperoxido h-sintase
SK286972B6 (sk) * 1997-08-22 2009-08-06 Abbott Laboratories Arylpyridazinóny ako inhibítory biosyntézy prostaglandín endoperoxid H syntázy, ich použitie a farmaceutická kompozícia s ich obsahom
BR9812127A (pt) * 1997-08-22 2000-07-18 Abbott Lab Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase

Also Published As

Publication number Publication date
CN1342149A (zh) 2002-03-27
CA2347982A1 (en) 2000-05-04
EP1124804A1 (en) 2001-08-22
JP2003512292A (ja) 2003-04-02
CZ300570B6 (cs) 2009-06-17
ATE302759T1 (de) 2005-09-15
SK5542001A3 (en) 2001-12-03
WO2000024719A1 (en) 2000-05-04
BR9914858A (pt) 2002-02-05
NO20012061D0 (no) 2001-04-26
BG65261B1 (bg) 2007-10-31
DE69926903D1 (en) 2005-09-29
CN1279026C (zh) 2006-10-11
NO20012061L (no) 2001-06-27
HK1041876A1 (en) 2002-07-26
PL198503B1 (pl) 2008-06-30
CZ20011481A3 (cs) 2001-09-12
HUP0105248A3 (en) 2002-09-30
KR100666838B1 (ko) 2007-01-11
SK286806B6 (sk) 2009-05-07
EP1124804B1 (en) 2005-08-24
KR20010081101A (ko) 2001-08-27
HK1041876B (en) 2006-06-23
HUP0105248A2 (hu) 2002-07-29
PL349256A1 (en) 2002-07-01
ES2249919T3 (es) 2006-04-01
DE69926903T2 (de) 2006-07-13
BG105523A (en) 2001-12-29
NO318623B1 (no) 2005-04-18
TR200101765T2 (tr) 2002-02-21

Similar Documents

Publication Publication Date Title
DK1124804T3 (da) Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase
DK1005460T3 (da) Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase
CA2299300A1 (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
Reddy et al. C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages
Arora et al. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review
Gedawy et al. Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors
Esser et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2
Carabaza et al. Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs
Chan et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
Zarghi et al. Synthesis and biological evaluation of 1, 3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors
Maiden Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy
Zschocke et al. Cryptocarya species—substitute plants for Ocotea bullata? A pharmacological investigation in terms of cyclooxygenase-1 and-2 inhibition
Chen et al. Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
EP1391201A4 (en) MEDICAL COMPOSITIONS
Lolli et al. A new class of ibuprofen derivatives with reduced gastrotoxicity
Noguchi et al. Thalidomide and its analogues as cyclooxygenase inhibitors
Singh Bahia et al. Inhibitors of microsomal prostaglandin E2 synthase‐1 enzyme as emerging anti‐inflammatory candidates
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Petrovic et al. Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro
Rasooli et al. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2
Varandas et al. Design, synthesis and pharmacological evaluation of new nonsteroidal antiinflammatory 1, 3, 4-thiadiazole derivatives
Aprioku et al. Renal effects of non-steroidal anti inflammatory drugs in albino rats
Zhu et al. Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.